Hoth Therapeutics, Inc.

NasdaqCM:HOTH Stock Report

Market Cap: US$5.9m

Hoth Therapeutics Balance Sheet Health

Financial Health criteria checks 6/6

Hoth Therapeutics has a total shareholder equity of $8.8M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $9.5M and $705.0K respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$9.29m
EquityUS$8.82m
Total liabilitiesUS$704.98k
Total assetsUS$9.52m

Recent financial health updates

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Companies Like Hoth Therapeutics (NASDAQ:HOTH) Could Be Quite Risky

Dec 02
Companies Like Hoth Therapeutics (NASDAQ:HOTH) Could Be Quite Risky

Recent updates

Hoth Therapeutics partners with Altasciences to manufacture HT-TBI for brain injury

Sep 20

Hoth Therapeutics granted grace days by Nasdaq to regain compliance with bid price rule

Jun 29

Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Nov 12
Here's Why We're Watching Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Situation

Hoth Therapeutics extends agreement for experimental antibiotic

Jun 18

We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Jun 10
We're Not Very Worried About Hoth Therapeutics' (NASDAQ:HOTH) Cash Burn Rate

Hoth Therapeutics expands research agreement with VCU for COVID-19 therapeutic

May 05

Hoth Therapeutics shares rise 10% on developmental plans for HT-KIT in multiple orphan diseases and rare cancers

May 03

Hoth provides pipeline and regulatory timeline update

Feb 02

FDA grants Hoth Therapeutics Pre-IND meeting for HT-001, shares up 15%

Jan 13

Hoth Therapeutics to initiate IND enabling studies of HT-001 in cancer

Jan 11

Hoth Therapeutics inks deal for treatment of multi-drug resistant bacterial lung infections, shares up 15%

Jan 04

Hoth therapeutics signs production agreement for HT-001, Shares up 75%

Dec 31

Companies Like Hoth Therapeutics (NASDAQ:HOTH) Could Be Quite Risky

Dec 02
Companies Like Hoth Therapeutics (NASDAQ:HOTH) Could Be Quite Risky

Hoth Therapeutics shows encouraging preclinical action in autoimmune skin disorder

Nov 03

Financial Position Analysis

Short Term Liabilities: HOTH's short term assets ($9.4M) exceed its short term liabilities ($678.7K).

Long Term Liabilities: HOTH's short term assets ($9.4M) exceed its long term liabilities ($26.3K).


Debt to Equity History and Analysis

Debt Level: HOTH is debt free.

Reducing Debt: HOTH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: HOTH has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: HOTH has sufficient cash runway for 1 years if free cash flow continues to reduce at historical rates of 22.9% each year.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.